After the Bell
Before the Bell
Jim Cramer's Daily Booyah
Winners & Losers
Earnings season is off to a good start. Here are five more stocks that could shoot higher this summer.
Celgene continues to sprinkle cash around the biotech sector, tying up with smaller companies for first-dibs access to potentially valuable drugs and technologies.
A pullback for Merck will lead to lower entry opportunities.
BMO Capital Markets downgrades the pharmaceutical giant ahead of Q2 earnings as pricing pressure mounts and other potential headwinds begin to emerge.
©1996-2016 TheStreet, Inc. All rights reserved.
Action Alerts PLUS is a registered trademark of TheStreet, Inc.